



IF IT DOESN'T SAY V.A.C.® THERAPY, IT'S NOT

The power of multiple elements used together, delivers true V.A.C.® Therapy outcomes

The unique V.A.C.® Therapy mechanism-of-action (MOA) combines Reticulated Open Cell Foam dressing, under true -125mmHg negative pressure, to create a biomechanical response that moves healing forward.¹⁻⁹

Customized healing across a broad range of wound types and care settings

- Chronic wounds
- Trauma wounds
- Donor site wounds
- Burns
- Incisions
- Open abdomen management

Innovation that improves efficiency and ease-of-use

- Proprietary **SENSAT.R.A.C.™ Technology** automatically monitors and adjusts to maintain optimal pressure setting
- Proactive **EASYCLEAR PURGE™ Technology** identifies and helps to resolve blockages, leaks, and erroneous alarms
- **V.A.C. VERAFLOR™ Therapy** combines NPWT with instillation and solution dwell time
- **PREVENA™ Therapy** actively manages linear and non-linear incisions
- **ABTHERA™ Open Abdomen Negative Pressure Therapy** is designed for simple and rapid application
- **V.A.C.RX4™ System** can treat up to 4 wounds, on a single patient, with a single device

The therapy you can trust—patient, after patient, after patient

10M+

wounds treated worldwide
with V.A.C.® Therapy¹⁰



Published clinical evidence¹⁰

1,291 vs. 61

total
V.A.C.® Therapy

total competitor
NPWT products



EFFECTIVE HEALING, IMPROVED EFFICIENCY

In a retrospective study of over **20,000** acute-care patients, V.A.C.® Therapy demonstrated lower total cost-of-care vs. competitor NPWT:^{11,A}

10%

shorter hospital length-of-stay^{11,B}

\$14,500

average savings in hospital
charges per patient^{11,C}

29-31%

fewer ER visits at 30 and
60-days post-discharge^{11,D}

10%

decrease in 30-day
rehospitalization rate^{11,E}

Partnership beyond products, every step of the way

- Live clinician training and on-site support (25,000 professionals trained annually¹⁰)
- 24-hour clinical and technical support for both clinicians and patients
- ACELITY™ Reimbursement Hotline staffed with specialists
- iOn HEALING™ Mobile App takes clinical support on the go
- V.A.C.® Therapy Free Product Evaluation Program

To learn more about what makes V.A.C.® Therapy the gold standard of NPWT, contact your ACELITY representative or visit vacfacts.com

Footnotes:

- A. Retrospective observational database study was conducted by Premier Research Services (PRS) to evaluate the costs and readmission rates of NPWT patients at facilities using V.A.C.® Therapy vs. competitor NPWT. Data analyses from 144 hospitals for V.A.C.® Therapy and 24 for competitor from 07/2011 to 06/2013; V.A.C.® Therapy (n= 18,385), Competitor NPWT (n= 3,253), (p=0.001). PRS included only those hospitals using procedural cost accounting. Dual hospitals were excluded. Patient cases were included for all indicated wound types. Each patient received at least 1 charge for NPWT. Data points falling in the lower and upper 0.05% were considered outliers and removed from summary calculations. Research funded by KCI. Data on file.
- B. Calculation based on 13.0 days V.A.C.® Therapy vs. 14.5 days competitor NPWT, (p<0.0001)
- C. Calculated based on total hospital charges of \$112,759 for V.A.C.® Therapy and \$127,272 competitor NPWT, (p<0.001)
- D. Calculation based on 16.6 visits V.A.C.® Therapy vs. 23.4 visits competitor NPWT at 30-days (p=0.0145), and 18.1 visits V.A.C.® Therapy vs. 26.2 visits competitor NPWT at 60-days (p=0.0012)
- E. Calculation based on 16.1% V.A.C.® Therapy vs. 17.9% competitor NPWT, (p=0.0145)

References:

1. Saxena V, Hwang CW, Huang S, Eichbaum Q, Ingber D, Orgill D. Vacuum-assisted closure: microdeformations of wounds and cell proliferation. *Plast Reconstr Surg.* 2004;114(5):1086-1096; discussion 1097-1098.
2. McNulty A, Schmidt M, Feely T, Kieswetter K. Effects of negative pressure wound therapy on fibroblast viability, chemotactic signaling, and proliferation in a provisional wound (fibrin) matrix. *Wound Repair Regen.* 2007;15(6):838-846.
3. McNulty A, Schmidt M, Feeley T, Villanueva P, Kieswetter K. Effects of negative pressure wound therapy on cellular energetics in fibroblasts grown in a provisional wound (fibrin) matrix. *Wound Repair Regen.* 2009;17(3):192-199.
4. Morykwas M, Argenta L, Shelton-Brown E, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. *Ann Plast Surg.* 1997;38(6):553-562.
5. Morykwas M, Simpson J, Pungler K, Argenta A, Kremers L, Argenta J. Vacuum-assisted closure: state of basic research and physiologic foundation. *Plast Reconstr Surg.* 2006;117(Suppl 7):121S-126S.
6. Baharestani M, de Leon J, Mendez-Eastman S, et al. Consensus statement: a practical guide for managing pressure ulcers with negative pressure wound therapy utilizing vacuum-assisted closure- understanding the treatment algorithm. *Adv in Skin & Wound Care.* 2008;21(Suppl 1):1-20.
7. Baharestani M, Driver V, de Leon J, Gabriel A, Kaplan M, Lantis J. Optimizing clinical and cost effectiveness with early intervention of V.A.C. Therapy. *Ostomy Wound Manage.* 2008;54(Suppl 11):1-15.
8. Kamolz L, Andel H, Haslik W, Winter W, Meissl G, Frey M. Use of subatmospheric pressure therapy to prevent burn wound progression in human: first experiences. *Burns.* 2004;30(3):253-258.
9. Wackenfors A, Sjogren J, Algotsson L, Gustafsson R, Ingemansson R, Malmso M. The effect of vacuum-assisted closure therapy on the pig femoral artery vasomotor responses. *Wound Repair Regen.* 2004;12(2):244-251.
10. Data on file.
11. Law A., Beach K. Hospital stay costs associated with negative pressure wound therapy. Poster Presented at: Symposium on Advanced Wound Care (SAWC); October 16-18, 2014, Las Vegas, NV.

NOTE: Specific indications, contraindications, warnings, precautions, and safety information exist for KCI products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.